Morgan Stanley
CNTB

Morgan Stanley’s Connect Biopharma Holdings CNTB Stock Holding History

Morgan Stanley’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6K Buy
8,639
+5,049
+141% +$12.2K ﹤0.01% 6813
2026
Q1 		$9.41K Buy
3,590
+1,381
+63% +$3.6K ﹤0.01% 6965
2025
Q4 		$6.23K Buy
2,209
+2,109
+2,109% +$4.5K ﹤0.01% 7013
2025
Q3 		$151 Hold
100
– – ﹤0.01% 7627
2025
Q2 		$98 Buy
+100
New +$80 ﹤0.01% 7652
2024
Q3 		– Sell
-3,568
Closed -$5.42K – 7944
2024
Q2 		$5.42K Buy
+3,568
New +$5.86K ﹤0.01% 6829
2023
Q4 		– Sell
-1
Closed -$1 – 7840
2023
Q3 		$1 Hold
1
– – ﹤0.01% 7600
2023
Q2 		$1 Hold
1
– – ﹤0.01% 7643
2023
Q1 		$1 Sell
1
-358
-100% -$390 ﹤0.01% 7701
2022
Q4 		$311 Sell
359
-7,732
-96% -$6.37K ﹤0.01% 7604
2022
Q3 		$10K Sell
8,091
-64
-0.8% -$77 ﹤0.01% 7062
2022
Q2 		$7K Sell
8,155
-681
-8% -$1K ﹤0.01% 7309
2022
Q1 		$27K Buy
8,836
+3,537
+67% +$14.9K ﹤0.01% 7005
2021
Q4 		$27K Buy
+5,299
New +$58.9K ﹤0.01% 7090
2021
Q3 		– Sell
-1,197
Closed -$23K – 7943
2021
Q2 		$23K Buy
+1,197
New +$20K ﹤0.01% 6954

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Morgan Stanley's CNTB Position: Q2 2026 in Review

Morgan Stanley increased its Connect Biopharma Holdings (CNTB) stake by 141% in Q2 2026, buying an estimated $12.2K and bringing the position to 8,639 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6813.

Morgan Stanley first reported a position in CNTB in Q2 2021 and has held it in 15 quarters since. The position peaked at $27K in Q1 2022. 56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • Morgan Stanley held 8,639 shares of Connect Biopharma Holdings worth $20.6K as of Q2 2026.
  • Morgan Stanley bought 5,049 Connect Biopharma Holdings shares in Q2 2026, an estimated $12.2K.
  • Connect Biopharma Holdings made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6813 holding.
  • Morgan Stanley first reported a position in Connect Biopharma Holdings in Q2 2021 and has held it in 15 quarters since.
  • Morgan Stanley's Connect Biopharma Holdings position peaked at $27K in Q1 2022.
  • 56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.